Immunosuppressants for therapy of patients with ulcerative colitis

Tadakazu Hisamatsu, Toshifumi Hibi

研究成果: Review article査読


Ulcerative colitis (UC) has been known as inflammatory bowel disease. Progress in UC management strategies has led to optimized approaches for achieving the two primary clinical goals of therapy: induction and maintenance of remission. We here review about immunosuppressants in management of UC; Cyclosporine A (CsA) has been used for the induction therapy in steroid resistant refractory UC. Although it has been reported that CsA has high response rate in severe UC, long-term efficacy (maintenance of remission) has not been proven. To improve maintenance therapy, immunosuppressant has been re-considered in management of UC. In recent years, it has been reported that efficacy of 6-mercaptopurine/azathioprine in maintenance of remission of UC is superior to 5-aminosalicylate (5-ASA). Pharmacological studies have indicated thiopurine methyltransferase (TPMT) activity is essential for maintenance of blood concentration of 6-thioguanine nucleotide (6-TG).

ジャーナルNippon rinsho. Japanese journal of clinical medicine
出版ステータスPublished - 2005 5月

ASJC Scopus subject areas

  • 医学(全般)


「Immunosuppressants for therapy of patients with ulcerative colitis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。